Faculty Opinions recommendation of Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.

2013 ◽  
Author(s):  
J Michael Kilby
Keyword(s):  
Clinical Trials ◽  
Tuberculosis Treatment ◽  
Virologic Suppression ◽  
Aids Clinical Trials

scholarly journals Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS)

2019 ◽  
Vol 221 (9) ◽  
pp. 1407-1415 ◽  
Author(s):  
Rajesh T Gandhi ◽  
Karen T Tashima ◽  
Laura M Smeaton ◽  
Vincent Vu ◽  
Justin Ritz ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Salvage Therapy ◽  
Virologic Failure ◽  
Virologic Suppression ◽  
Cumulative Activity ◽  
Antiretroviral Medications ◽  
Resistant Group ◽  
Aids Clinical Trials ◽  
Hiv 1

Abstract Background Short-term (48-week) results of the OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) can be safely omitted from salvage therapy as long as the regimen has a cumulative activity of >2 active antiretroviral medications. The long-term durability of this approach and outcomes in persons who have more-extensive HIV-1 drug resistance are uncertain. Methods Participants with virologic failure and anticipated antiretroviral susceptibility received an optimized regimen and were randomized to omit or add NRTIs. A separate group with more resistance (cumulative activity ≤2 active agents) received an optimized regimen including NRTIs. Results At week 96, among 360 participants randomized to omit or add NRTIs, 70% and 65% had HIV-1 RNA <200 copies/mL, respectively. Virologic failure was uncommon after week 48. Younger age and starting fewer new antiretroviral medications were associated with higher odds of virologic failure. In the highly resistant group, 53% had HIV-1 RNA <200 copies/mL at week 96. Conclusions HIV-1 salvage therapy can safely omit NRTIs without compromising efficacy or durability of response as long as the new regimen has a cumulative activity of >2 active drugs. Younger people and those receiving fewer new antiretrovirals require careful monitoring. Even among individuals with more-extensive resistance, most achieve virologic suppression. Clinical Trials Registration NCT00537394.

scholarly journals Community-Researcher Partnerships at NIAID HIV/AIDS Clinical Trials Sites: Insights for Evaluation and Enhancement

2012 ◽  
Vol 6 (3) ◽  
pp. 311-320 ◽  
Author(s):  
Jonathan M. Kagan ◽  
Scott R. Rosas ◽  
Rona L. Siskind ◽  
Russell D. Campbell ◽  
Daniel Gondwe ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Aids Clinical Trials ◽  
Hiv Aids

Use of Complementary Medicine by Adult Patients Participating in HIV/AIDS Clinical Trials

2000 ◽  
Vol 6 (5) ◽  
pp. 415-422 ◽  
Author(s):  
Andrew Sparber ◽  
Jacqueline C. Wootton ◽  
Larry Bauer ◽  
Gregory Curt ◽  
David Eisenberg ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Complementary Medicine ◽  
Adult Patients ◽  
Aids Clinical Trials ◽  
Hiv Aids

scholarly journals How Researchers Define Vulnerable Populations in HIV/AIDS Clinical Trials

2010 ◽  
Vol 14 (6) ◽  
pp. 1313-1319 ◽  
Author(s):  
Sohini Sengupta ◽  
Bernard Lo ◽  
Ronald P. Strauss ◽  
Joseph Eron ◽  
Allen L. Gifford
Keyword(s):  
Clinical Trials ◽  
Vulnerable Populations ◽  
Aids Clinical Trials ◽  
Hiv Aids
Sign in / Sign up

Export Citation Format

Share Document